682 related articles for article (PubMed ID: 34403877)
1. A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation.
Chen L; Kan J; Zheng N; Li B; Hong Y; Yan J; Tao X; Wu G; Ma J; Zhu W; Sheng L; Chen L; Li B; Zhong J; Du J; Li H
Phytomedicine; 2021 Oct; 91():153693. PubMed ID: 34403877
[TBL] [Abstract][Full Text] [Related]
2. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
4. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.
Chen L-p; Zhang L-f; Liu S; Hua H; Zhang L; Liu B-c; Wang R-r
Microbiol Spectr; 2024 Jun; 12(6):e0197923. PubMed ID: 38647315
[TBL] [Abstract][Full Text] [Related]
5. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
Wang P; Wang J; Li D; Ke W; Chen F; Hu X
J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
[TBL] [Abstract][Full Text] [Related]
6. Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse.
Lee JE; Lee SM; Jung J
Phytomedicine; 2020 Dec; 79():153354. PubMed ID: 32992082
[TBL] [Abstract][Full Text] [Related]
7. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
[TBL] [Abstract][Full Text] [Related]
8. The modulation of Luffa cylindrica (L.) Roem supplementation on gene expression and amino acid profiles in liver for alleviating hepatic steatosis via gut microbiota in high-fat diet-fed mice: insight from hepatic transcriptome analysis.
Zhang L; Wang P; Shi M; Fang Z; Ji J; Liao X; Hu X; Chen F
J Nutr Biochem; 2020 Jun; 80():108365. PubMed ID: 32217466
[TBL] [Abstract][Full Text] [Related]
9. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
[TBL] [Abstract][Full Text] [Related]
10. Tectorigenin ameliorated high-fat diet-induced nonalcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in mice.
Duan R; Huang K; Guan X; Li S; Xia J; Shen M; Sun Z; Yu Z
Food Chem Toxicol; 2022 Jun; 164():112948. PubMed ID: 35390440
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen inhalation ameliorates hepatic inflammation and modulates gut microbiota in rats with high-fat diet-induced non-alcoholic fatty liver disease.
Xue J; Zhao M; Liu Y; Jia X; Zhang X; Gu Q; Xie Y; Qin S; Liu B
Eur J Pharmacol; 2023 May; 947():175698. PubMed ID: 36997047
[TBL] [Abstract][Full Text] [Related]
12. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
Wang W; Zhao J; Gui W; Sun D; Dai H; Xiao L; Chu H; Du F; Zhu Q; Schnabl B; Huang K; Yang L; Hou X
Br J Pharmacol; 2018 Feb; 175(3):469-484. PubMed ID: 29139555
[TBL] [Abstract][Full Text] [Related]
13. Anti-NAFLD effect of defatted walnut powder extract in high fat diet-induced C57BL/6 mice by modulating the gut microbiota.
Ren SM; Zhang QZ; Chen ML; Jiang M; Zhou Y; Xu XJ; Wang DM; Pan YN; Liu XQ
J Ethnopharmacol; 2021 Apr; 270():113814. PubMed ID: 33444725
[TBL] [Abstract][Full Text] [Related]
14. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
[TBL] [Abstract][Full Text] [Related]
15. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
[TBL] [Abstract][Full Text] [Related]
16. Modulation of gut microbiota by glycyrrhizic acid may contribute to its anti-NAFLD effect in rats fed a high-fat diet.
Wang S; Li XY; Ji HF; Shen L
Life Sci; 2022 Dec; 310():121110. PubMed ID: 36272466
[TBL] [Abstract][Full Text] [Related]
17. Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism.
Huang X; Chen Q; Fan Y; Yang R; Gong G; Yan C; Song Y; Zhang B; Xi S; Huang Y; Xu H
Biomed Pharmacother; 2023 Mar; 159():114300. PubMed ID: 36696803
[TBL] [Abstract][Full Text] [Related]
18. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
[TBL] [Abstract][Full Text] [Related]
19.
Riezu-Boj JI; Barajas M; Pérez-Sánchez T; Pajares MJ; Araña M; Milagro FI; Urtasun R
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558371
[TBL] [Abstract][Full Text] [Related]
20. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats.
Shen SH; Zhong TY; Peng C; Fang J; Lv B
BMC Complement Med Ther; 2020 Feb; 20(1):34. PubMed ID: 32024509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
